Preparation Of Aluminum Phosphate Or Polyphosphate Particles

Resumo não disponível.EA014670 (B1); EA200970191 (A1)C01B25/36C01B25/40C08K3/32C09C1/40C09D5/00C09D7/12C09D11/00C09D11/02EA20090070191C01B25/36C01B25/40C08K3/32C09C1/40C09D5/00C09D7/12C09D11/00C09D11/02US2006045831 (A1)US4542001 (A)FR2157866 (A1)US6022513 (A

Preparation Of Aluminum Phosphate Or Polyphosphate Particles

Patente de Invenção:"PREPARAÇÃO DE PARTÍCULAS DE FOSFATO OU DE POLIFOSFATO DE ALUMÍNIO". A presente invenção refere-se a um processo para a preparação de um pigmento com base em um fosfato ou de um polifosfato de alumínio amorfo através da reação do fosfato de alumínio e aluminato de sódio. O fosfato ou o polifosfato de alumínio amorfo é caracterizado através de uma densidade esquelética de menos do que 2,50 gramas por centímetro cúbico e uma proporção molar de fósforo para alumínio maior do que 1. Em uma modalidade, a composição é útil em tintas como um substituto para o dióxido de titânio.BRPI0715813 (A2)C01B25/36C01B25/40C08K3/32C09C1/40C09D5/00C09D7/12C09D11/00C09D11/02BR2007PI15813C01B25/36C01B25/40C08K3/32C09C1/40C09D5/00C09D7/12C09D11/00C09D11/0

Preparation Of Aluminum Phosphate Or Polyphosphate Particles

A process for the preparation of amorphous aluminum phosphate or polyphosphate-based pigment by reacting aluminum phosphate and sodium aluminate is provided. The amorphous aluminum phosphate or polyphosphate is characterized by a skeletal density of less than 2.50 grams per cubic centimeter and a phosphorus to aluminum mole ratio of greater than 1. In one embodiment, the composition is useful in paints as a substitute for titanium dioxide.CA2660564 (C); CA2660564 (A1)C01B25/36C01B25/40C08K3/32C09C1/40C09D5/00C09D7/12C09D11/00C09D11/02CA20072660564C01B25/36C01B25/40C08K3/32C09C1/40C09D5/00C09D7/12C09D11/00C09D11/0

Antitumor activity of oxaliplatin in neuroblastoma cell lines

Imatinib mesylate has antitumor activity in vitro and in vivo against neuroblastoma cell lines and xenografts characterized by a different expression of receptor tyrosine kinases. In this article, we report that imatinib tumor concentration can be independent of the administered dose and does not correlate with the antitumor effect. In xenografts, high-dose administration does not improve imatinib efficacy. In conclusion, there is no clear-cut correlation between the levels of expression for imatinib-responsive targets and the in vitro and in vivo sensitivity. This further suggests that in neuroblastoma the antitumor activity of imatinib may involve the inhibition of other tyrosine kinases and/or pathways

Preparation Of Aluminum Phosphate Or Polyphosphate Particles

Resumo não disponível.CO6160215 (A2)C01B25/36C01B25/40C09C1/40C09D11/02CO20090013898C01B25/36C01B25/40C09C1/40C09D11/0

CLINICAL PHARMACOKINETICS OF CARBOPLATIN IN CHILDREN

The present study was undertaken to evaluate in children the plasma pharmacokinetics of free carboplatin given at different doses and schedules and to evaluate the inter- and intrapatient variability and the possible influence of schedule on drug exposure. A total of 35 children (age range, 1-17 years) with malignant tumors were studied. All patients had normal renal function (creatinine clearance corrected for surface body area, above 70 ml min(-1) m(-2); range, 71-151 ml min(-1) m(-2)) and none had renal involvement by malignancy. Carboplatin was given at the following doses and schedules: 175, 400, 500, and 600 mg/ m(2) given as a l-h infusion; 1,200 mg/m(2) divided into equal doses and infused over 1 h on 2 consecutive days; and 875 and 1,200 mg/m(2) given as a 5-day continuous infusion. A total of 57 courses were studied. Carboplatin levels in plasma ultrafiltrate (UF) samples were measured both by high-performance liquid chromatography and by atomic absorption spectrophotometry. Following a 1-h infusion, carboplatin free plasma levels decayed biphasically; the disappearance half-lives, total body clearance, and apparent volume of distribution were similar for different doses. In children with normal renal function as defined by creatinemia and blood urea nitrogen (BUN) and creatinine clearance, we found at each dose studied a limited interpatient variability of the peak plasma concentration (C-max) and the area under the concentration-time curve (AUC) and a linear correlation between the dose and both C-max (r = 0.95) and AUC (r = 0.97). The mean value +/- SD for the dose-normalized AUC was 13+/-2 min m(2) 1(-1) (n = 57). The administration schedule does not seem to influence drug exposure, since prolonged i.v. infusion or bolus administration of 1,200 mg/m(2) achieved a similar AUC (13.78+/-2.90 and 15.05+/-1.44 mg ml(-1) min, respectively). In the nine children studied during subsequent courses a limited interpatient variability was observed and no correlation (r = 0.035) was found between AUC and subsequent courses by a multivariate analysis of dose, AUC, and course number. The pharmacokinetic parameters were similar to those previously reported in adults; however, a weak correlation (r = 0.52, P = 0.03) between carboplatin total body clearance and creatinine clearance varying within the normal range was observed. A dosing formula appears unnecessary in children with normal renal function since a generally well-predictable free carboplatin AUC is achieved following a given dose